B+
Bull case
25%
Probability
Target price
$3.60
+93.5% vs current
PALI
Palisade BioBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.80
-3.2% vs current
B-
Bear case
30%
Probability
Target price
$0.90
-51.6% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+55.4
Score
AI commentary
Sentiment is improved versus a pure financing-stress story because the 2025 equity raise removed near-term going-concern pressure and the April 2026 8-K tied new capital to Phase 2 enrollment preparation. Even so, forward visibility is still limited, the setup remains binary, and the deterministic prior stays negative, so this reads as a cautious monitoring name rather than a high-conviction bullish thesis [#8-K-2026-04-02] [#10-K-2026-03-20].
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-31catalystOperational follow-through from Iterative Health enrollment agreementHigh impact
Palisade said it hired Iterative Health to help expedite enrollment for the expected Phase 2 ulcerative colitis study and sold 1,536,885 shares to an Iterative affiliate for $3.0 million at $1.952 per share. Near-term disclosure that this support is translating into site activation or enrollment progress would help validate execution, while silence would keep the name in monitoring mode [#8-K-2026-04-02].
2026-06-30eventPlanned FDA IND submission for Phase 2 UC studyHigh impact
The 2025 10-K says management anticipates the Phase 1/1b UC program and exploratory FSCD cohort will support an FDA IND submission for a Phase 2 UC study in the second quarter of 2026. A clean regulatory step would improve visibility, but the same filing also states there is no assurance the FDA will accept the Canadian trial data or allow a U.S. Phase 2 to proceed [#10-K-2026-03-20].
2027-09-30catalystPhase 2 UC efficacy path for PALI-2108High impact
The 10-K says Palisade believes it has capital to fund operations through major clinical milestones, including a Phase 2 primary efficacy readout for PALI-2108 in UC expected in the second half of 2027. That is the main long-duration value inflection, but it remains a low-visibility, binary biotech setup before proof-of-concept [#10-K-2026-03-20].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology